Long-term Follow-up and Outcome of Phenylketonuria Patients on Sapropterin: A Retrospective Study

OBJECTIVE: Sapropterin dihydrochloride, the synthetic form of 6R-tetrahydrobiopterin (BH4), is an approved drug for the treatment of patients with BH4-responsive phenylketonuria (PKU). The purpose of this study was to assess genotypes and data on the long-term effects of BH4/sapropterin on metabolic control and patient-related outcomes in 6 large European countries. METHODS: A questionnaire was developed to assess phenotype, genotype, blood phenylalanine (Phe) levels, Phe tolerance, quality of life, mood changes, and adherence to diet in PKU patients from 16 medical centers. RESULTS: One hundred forty-seven patients, of whom 41.9% had mild hyperphenylalaninemia, 50.7% mild PKU, and 7.4% classic PKU, were followed up over ≤12 years. A total of 85 different genotypes were reported. With the exception of two splice variants, all of the most common mutations were reported to be associated with substantial residual Phe hydroxylase activity. Median Phe tolerance increased 3.9 times with BH4/sapropterin therapy, compared with dietary treatment, and median Phe blood concentrations were within the therapeutic range in all patients. Compared with diet alone, improvement in quality of life was reported in 49.6% of patients, improvement in adherence to diet was reported in 47% of patients, and improvement in adherence to treatment was reported in 63.3% of patients. No severe adverse events were reported. CONCLUSIONS: Our data document a long-term beneficial effect of orally administered BH4/sapropterin in responsive PKU patients by improving the metabolic control, increasing daily tolerance for dietary Phe intake, and for some, by improving dietary adherence and quality of life. Patient genotypes help in predicting BH4 responsiveness.

[1]  N. Blau,et al.  Phenylketonuria , 1961, The Lancet.

[2]  S. Cederbaum,et al.  Recommendations for evaluation of responsiveness to tetrahydrobiopterin (BH(4)) in phenylketonuria and its use in treatment. , 2007, Molecular genetics and metabolism.

[3]  A. Chakrapani,et al.  Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study , 2007, The Lancet.

[4]  P. Fernhoff,et al.  Safety of extended treatment with sapropterin dihydrochloride in patients with phenylketonuria: results of a phase 3b study. , 2011, Molecular genetics and metabolism.

[5]  N. Blau,et al.  Genotype-predicted tetrahydrobiopterin (BH4)-responsiveness and molecular genetics in Croatian patients with phenylalanine hydroxylase (PAH) deficiency. , 2009, Molecular genetics and metabolism.

[6]  J. Walter,et al.  Blood phenylalanine control in adolescents with phenylketonuria , 2004, International journal of adolescent medicine and health.

[7]  A. Roscher,et al.  Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. , 2002, The New England journal of medicine.

[8]  N. Blau,et al.  The metabolic and molecular bases of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. , 2004, Molecular genetics and metabolism.

[9]  E. Jurecki,et al.  Evolving patient selection and clinical benefit criteria for sapropterin dihydrochloride (Kuvan®) treatment of PKU patients. , 2012, Molecular genetics and metabolism.

[10]  S. Cederbaum,et al.  Recommendations for the use of sapropterin in phenylketonuria. , 2012, Molecular genetics and metabolism.

[11]  N. Blau,et al.  Assessment of tetrahydrobiopterin (BH4) responsiveness in phenylketonuria. , 2007, The Journal of pediatrics.

[12]  Nenad Blau,et al.  Molecular genetics and impact of residual in vitro phenylalanine hydroxylase activity on tetrahydrobiopterin responsiveness in Turkish PKU population. , 2011, Molecular genetics and metabolism.

[13]  C. Hollak,et al.  The 48-hour tetrahydrobiopterin loading test in patients with phenylketonuria: evaluation of protocol and influence of baseline phenylalanine concentration. , 2011, Molecular genetics and metabolism.

[14]  N. Blau,et al.  Pathogenesis of cognitive dysfunction in phenylketonuria: review of hypotheses. , 2010, Molecular genetics and metabolism.

[15]  A. Sitta,et al.  Optimized loading test to evaluate responsiveness to tetrahydrobiopterin (BH4) in Brazilian patients with phenylalanine hydroxylase deficiency. , 2011, Molecular genetics and metabolism.

[16]  S. Dobrowolski,et al.  Utility of phenylalanine hydroxylase genotype for tetrahydrobiopterin responsiveness classification in patients with phenylketonuria. , 2012, Molecular genetics and metabolism.

[17]  D. Solís.  US Food and Drug Administration , 2010 .

[18]  J. Vockley,et al.  Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. , 2009, The Journal of pediatrics.

[19]  N. Blau,et al.  The interplay between genotype, metabolic state and cofactor treatment governs phenylalanine hydroxylase function and drug response. , 2011, Human molecular genetics.

[20]  N. Blau,et al.  Tetrahydrobiopterin, its Mode of Action on Phenylalanine Hydroxylase, and Importance of Genotypes for Pharmacological Therapy of Phenylketonuria , 2013, Human mutation.

[21]  National Institutes of Health Consensus Development Conference Statement: phenylketonuria: screening and management, October 16-18, 2000. , 2001, Pediatrics.

[22]  N. Blau,et al.  High frequency of tetrahydrobiopterin-responsiveness among hyperphenylalaninemias: a study of 1,919 patients observed from 1988 to 2002. , 2002, Molecular genetics and metabolism.

[23]  S. Kure,et al.  Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. , 1999, The Journal of pediatrics.

[24]  M. Couce,et al.  New evidence for assessing tetrahydrobiopterin (BH(4)) responsiveness. , 2012, Metabolism: clinical and experimental.

[25]  S. Huijbregts,et al.  Cognitive, neurophysiological, neurological and psychosocial outcomes in early-treated PKU-patients: a start toward standardized outcome measurement across development. , 2011, Molecular genetics and metabolism.

[26]  A. Macdonald,et al.  Adjusting diet with sapropterin in phenylketonuria: what factors should be considered? , 2011, British Journal of Nutrition.

[27]  E. Werner,et al.  Tetrahydrobiopterin: biochemistry and pathophysiology. , 2011, The Biochemical journal.

[28]  N. Blau,et al.  Long-term treatment with tetrahydrobiopterin increases phenylalanine tolerance in children with severe phenotype of phenylketonuria. , 2005, Molecular genetics and metabolism.

[29]  C. Whitley,et al.  START, a double blind, placebo-controlled pharmacogenetic test of responsiveness to sapropterin dihydrochloride in phenylketonuria patients. , 2012, Molecular genetics and metabolism.

[30]  S. Cederbaum,et al.  The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study , 2007, Journal of Inherited Metabolic Disease.

[31]  U. R. Somaraju,et al.  Sapropterin dihydrochloride for phenylketonuria. , 2015, The Cochrane database of systematic reviews.

[32]  N. Blau,et al.  Challenges and Pitfalls in the Management of Phenylketonuria , 2010, Pediatrics.

[33]  N. Blau,et al.  Optimizing the use of sapropterin (BH(4)) in the management of phenylketonuria. , 2009, Molecular genetics and metabolism.

[34]  N. Blau,et al.  Assessment of Tetrahydrobiopterin (BH 4) Responsiveness in Phenylketonuria , 2007 .

[35]  N. Blau,et al.  Effect of BH4 supplementation on phenylalanine tolerance , 2009, Journal of Inherited Metabolic Disease.

[36]  T. Battelino,et al.  Assessment of tetrahydrobiopterin (BH(4))-responsiveness and spontaneous phenylalanine reduction in a phenylalanine hydroxylase deficiency population. , 2012, Molecular genetics and metabolism.

[37]  N. Blau,et al.  Management of phenylketonuria in Europe: survey results from 19 countries. , 2010, Molecular genetics and metabolism.

[38]  M. Seashore,et al.  Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria , 2008, American journal of medical genetics. Part A.

[39]  U. Ceglarek,et al.  Tetrahydrobiopterin (BH4) in PKU: effect on dietary treatment, metabolic control, and quality of life , 2012, Journal of Inherited Metabolic Disease.

[40]  Aurora Martínez,et al.  Quantification of phenylalanine hydroxylase activity by isotope-dilution liquid chromatography-electrospray ionization tandem mass spectrometry. , 2012, Molecular genetics and metabolism.

[41]  R. Artuch,et al.  Clinical and nutritional evaluation of phenylketonuric patients on tetrahydrobiopterin monotherapy. , 2005, Molecular genetics and metabolism.